The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women

A family study

Daniela Tormene, V. De Stefano, E. Grandone, T. Za, M. Perlati, E. Rossi, M. Margaglione, P. Simioni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The relationship between the G20210A prothrombin variant (PT-G20210A) and adverse pregnancy outcome has been studied by several groups in the last few years. However, because of the different design and sample sizes of these studies the estimated risks have varied. Objective: In this retrospective, multi-center, cohort study we assessed the risk of thromboembolic or obstetric complications in women belonging to families of probands with isolated PT-G20210A and that were symptomatic for venous thromboembolism (VTE). Methods: Two hundred and eighty-three female family members that had been pregnant at least once were enrolled. The occurrence of VTE and obstetric complications during pregnancy and postpartum were assessed in carriers of PT-G20210A and compared with non- carriers. Results: One thromboembolic event occurred during the postpartum period in the carriers group. In the same group, 48 out of 359 pregnancies resulted in unexplained fetal loss as compared with 50 out of 357 pregnancies in the non-carriers (RR 0.9; 95% CI: 0.7-1.4). After adjustment, carriers of PT-G20210A showed a trend towards a higher risk of late fetal loss as compared with non-carriers (RR 2.2; 95% CI: 0.8-6.2). Furthermore, in pregnancies subsequent to those with previous fetal loss there was not a different risk of adverse outcome regardless of the carrier status. Conclusions: Female family members who are heterozygous carriers of isolated PT-G20210A do not seem to be at significant increased risk for fetal loss as compared with non-carriers. Screening for PT-G20210A of fertile age women belonging to these families is not warranted in this situation.

Original languageEnglish
Pages (from-to)2193-2196
Number of pages4
JournalJournal of Thrombosis and Haemostasis
Volume5
Issue number11
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Venous Thromboembolism
Prothrombin
Pregnant Women
Pregnancy
Postpartum Period
Obstetrics
Social Adjustment
Pregnancy Complications
Pregnancy Outcome
Sample Size
Cohort Studies

Keywords

  • Aspirin
  • Platelet activation markers
  • Type-2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women : A family study. / Tormene, Daniela; De Stefano, V.; Grandone, E.; Za, T.; Perlati, M.; Rossi, E.; Margaglione, M.; Simioni, P.

In: Journal of Thrombosis and Haemostasis, Vol. 5, No. 11, 11.2007, p. 2193-2196.

Research output: Contribution to journalArticle

Tormene, Daniela ; De Stefano, V. ; Grandone, E. ; Za, T. ; Perlati, M. ; Rossi, E. ; Margaglione, M. ; Simioni, P. / The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women : A family study. In: Journal of Thrombosis and Haemostasis. 2007 ; Vol. 5, No. 11. pp. 2193-2196.
@article{c35329f2ed0f47f68c53b1f3cf9c630a,
title = "The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: A family study",
abstract = "Background: The relationship between the G20210A prothrombin variant (PT-G20210A) and adverse pregnancy outcome has been studied by several groups in the last few years. However, because of the different design and sample sizes of these studies the estimated risks have varied. Objective: In this retrospective, multi-center, cohort study we assessed the risk of thromboembolic or obstetric complications in women belonging to families of probands with isolated PT-G20210A and that were symptomatic for venous thromboembolism (VTE). Methods: Two hundred and eighty-three female family members that had been pregnant at least once were enrolled. The occurrence of VTE and obstetric complications during pregnancy and postpartum were assessed in carriers of PT-G20210A and compared with non- carriers. Results: One thromboembolic event occurred during the postpartum period in the carriers group. In the same group, 48 out of 359 pregnancies resulted in unexplained fetal loss as compared with 50 out of 357 pregnancies in the non-carriers (RR 0.9; 95{\%} CI: 0.7-1.4). After adjustment, carriers of PT-G20210A showed a trend towards a higher risk of late fetal loss as compared with non-carriers (RR 2.2; 95{\%} CI: 0.8-6.2). Furthermore, in pregnancies subsequent to those with previous fetal loss there was not a different risk of adverse outcome regardless of the carrier status. Conclusions: Female family members who are heterozygous carriers of isolated PT-G20210A do not seem to be at significant increased risk for fetal loss as compared with non-carriers. Screening for PT-G20210A of fertile age women belonging to these families is not warranted in this situation.",
keywords = "Aspirin, Platelet activation markers, Type-2 diabetes",
author = "Daniela Tormene and {De Stefano}, V. and E. Grandone and T. Za and M. Perlati and E. Rossi and M. Margaglione and P. Simioni",
year = "2007",
month = "11",
doi = "10.1111/j.1538-7836.2007.02727.x",
language = "English",
volume = "5",
pages = "2193--2196",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women

T2 - A family study

AU - Tormene, Daniela

AU - De Stefano, V.

AU - Grandone, E.

AU - Za, T.

AU - Perlati, M.

AU - Rossi, E.

AU - Margaglione, M.

AU - Simioni, P.

PY - 2007/11

Y1 - 2007/11

N2 - Background: The relationship between the G20210A prothrombin variant (PT-G20210A) and adverse pregnancy outcome has been studied by several groups in the last few years. However, because of the different design and sample sizes of these studies the estimated risks have varied. Objective: In this retrospective, multi-center, cohort study we assessed the risk of thromboembolic or obstetric complications in women belonging to families of probands with isolated PT-G20210A and that were symptomatic for venous thromboembolism (VTE). Methods: Two hundred and eighty-three female family members that had been pregnant at least once were enrolled. The occurrence of VTE and obstetric complications during pregnancy and postpartum were assessed in carriers of PT-G20210A and compared with non- carriers. Results: One thromboembolic event occurred during the postpartum period in the carriers group. In the same group, 48 out of 359 pregnancies resulted in unexplained fetal loss as compared with 50 out of 357 pregnancies in the non-carriers (RR 0.9; 95% CI: 0.7-1.4). After adjustment, carriers of PT-G20210A showed a trend towards a higher risk of late fetal loss as compared with non-carriers (RR 2.2; 95% CI: 0.8-6.2). Furthermore, in pregnancies subsequent to those with previous fetal loss there was not a different risk of adverse outcome regardless of the carrier status. Conclusions: Female family members who are heterozygous carriers of isolated PT-G20210A do not seem to be at significant increased risk for fetal loss as compared with non-carriers. Screening for PT-G20210A of fertile age women belonging to these families is not warranted in this situation.

AB - Background: The relationship between the G20210A prothrombin variant (PT-G20210A) and adverse pregnancy outcome has been studied by several groups in the last few years. However, because of the different design and sample sizes of these studies the estimated risks have varied. Objective: In this retrospective, multi-center, cohort study we assessed the risk of thromboembolic or obstetric complications in women belonging to families of probands with isolated PT-G20210A and that were symptomatic for venous thromboembolism (VTE). Methods: Two hundred and eighty-three female family members that had been pregnant at least once were enrolled. The occurrence of VTE and obstetric complications during pregnancy and postpartum were assessed in carriers of PT-G20210A and compared with non- carriers. Results: One thromboembolic event occurred during the postpartum period in the carriers group. In the same group, 48 out of 359 pregnancies resulted in unexplained fetal loss as compared with 50 out of 357 pregnancies in the non-carriers (RR 0.9; 95% CI: 0.7-1.4). After adjustment, carriers of PT-G20210A showed a trend towards a higher risk of late fetal loss as compared with non-carriers (RR 2.2; 95% CI: 0.8-6.2). Furthermore, in pregnancies subsequent to those with previous fetal loss there was not a different risk of adverse outcome regardless of the carrier status. Conclusions: Female family members who are heterozygous carriers of isolated PT-G20210A do not seem to be at significant increased risk for fetal loss as compared with non-carriers. Screening for PT-G20210A of fertile age women belonging to these families is not warranted in this situation.

KW - Aspirin

KW - Platelet activation markers

KW - Type-2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=35448948400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448948400&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2007.02727.x

DO - 10.1111/j.1538-7836.2007.02727.x

M3 - Article

VL - 5

SP - 2193

EP - 2196

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 11

ER -